Association of serum angiopoietin-1, angiopoietin-2 and angiopoietin-2 to angiopoietin-1 ratio with heart failure in patients with acute myocardial infarction

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 937-941

  Chen, Shaomin ^a,b,c   Guo, Lijun ^a,b,c   Chen, Baoxia ^a,b,c   Sun, Lijie ^a,b,c   Cui, Ming ^a,b,c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Acute myocardial infarction; Angiopoietin; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84873154212     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.893     Document Type: Article

References (27)

1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: Eur Heart J 33: 2569-2619, 2012.
2. Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169, 1996.
3. Thomas M and Augustin HG: The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12: 125-137, 2009.
4. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
5. Post S, Peeters W, Busser E, et al: Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 45: 244-250, 2008.
6. Patel JV, Lim HS, Varughese GI, Hughes EA and Lip GY: Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 40: 215-222, 2008.
7. Iribarren C, Phelps BH, Darbinian JA, et al: Circulating angiopoietins-1 and-2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study. BMC Cardiovasc Disord 11: 31, 2011.
8. Chen J, Yu H, Sun K, et al: Promoter variant of angiopoietin-2 and plasma angiopoietin-2 are associated with risk of stroke recurrence in lacunar infarct patients. Biochem Biophys Res Commun 398: 212-216, 2010.
9. Chen S, Guo L, Cui M, Sun L and Mi L: Dynamic changes in serum angiopoietin-1, angiopoietin-2 and angiopoietin-2/angiopoietin-1 ratio in acute myocardial infarction patients treated with primary percutaneous coronary intervention. Biomarkers17: 441-446, 2012.
10. Lee KW, Lip GY and Blann AD: Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in acute coronary syndromes. Circulation110: 2355-2360, 2004.
11. Nadar SK, Blann A, Beevers DG and Lip GY: Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 258: 336-343, 2005.
12. Findley CM, Mitchell RG, Duscha BD, Annex BH and KontosCD: Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 52: 387-393, 2008.
13. Lim HS, Blann AD, Chong AY, Freestone B and Lip GY: Plasma vascular endothelial growth factor, angiopoietin-1 and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27: 2918-2924, 2004.
14. Di Stefano R, Felice F and Balbarini A: Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15: 1095-1106, 2009.
15. Dallabrida SM, Ismail N, Oberle JR, Himes BE and RupnickMA: Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96: e8-e24, 2005.
16. Jeansson M, Gawlik A, Anderson G, et al: Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 121: 2278-2289, 2011.
17. Chong AY, Caine GJ, Freestone B, Blann AD and Lip GY: Plasma angiopoietin-1, angiopoietin-2 and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 43: 423-438, 2004.
18. Eleuteri E, Di Stefano A, Tarro Genta F, et al: Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur J Cardiovasc Prev Rehabil 18: 607-614, 2011.
19. Buchner S, Debl K, Barlage S, et al: Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome. Clin Chem Lab Med 48: 875-881, 2010.
20. Ricciuto DR, dos Santos CC, Hawkes M, et al: Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 39: 702-710, 2011.
21. Ong T, McClintock DE, Kallet RH, Ware LB, Matthay MA and Liu KD: Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med 38: 1845-1851, 2010.
22. Turer AT and Hill JA: Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 106: 360-368, 2010.
23. van der Heijden M, van Nieuw Amerongen GP, van Bezu J, PaulMA, Groeneveld AB and van Hinsbergh VW: Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. PLoS One 6: e23448, 2011.
24. Fiedler U, Reiss Y, Scharpfenecker M, et al: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239, 2006.
25. Gu H, Cui M, Bai Y, et al: Angiopoietin-1/Tie2 signaling pathway inhibits lipopolysaccharide-induced activation of RAW264.7 macrophage cells. Biochem Biophys Res Commun 392: 178-182, 2010.
26. Tuo QH, Zeng H, Stinnett A, et al: Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol 294: 2547-2557, 2008.
27. Lee SW, Won JY, Lee HY, et al: Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade. Mol Med 17: 1095-1106, 2011.